International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations

Abstract

Diabetes is a significant and growing concern, with over 246 million people around the world living with the disease and another 308 million with impaired glucose tolerance. Depending on the resources of different nations, intervention has generally focused on optimizing overall glycaemic control as assessed by glycated haemoglobin (HbA 1c ) and fasting plasma glucose (FPG) values. Nevertheless, increasing evidence supports the importance of controlling all three members of the glucose triad, namely HbA 1c , FPG and postmeal glucose (PMG) in order to improve outcome in diabetes. As part of its global mission to promote diabetes care and prevention and to find a cure, the International Diabetes Federation (IDF) recently developed a guideline that reviews evidence to date on PMG and the development of diabetic complications. Based on an extensive database search of the literature, and guided by a Steering and Development Committee including experts from around the world, the IDF Guideline for Management of Postmeal Glucose offers recommendations for appropriate clinical management of PMG. These recommendations are intended to help clinicians and organizations in developing strategies for effective management of PMG in individuals with Type 1 and Type 2 diabetes. The following review highlights the recommendations of the guideline, the supporting evidence provided and the major conclusions drawn. The full guideline is available for download at http://www.idf.org .

Shown for reading. Its publisher allows quoting it, not republishing it.

References 50

1. 1.

   International Diabetes Federation. Diabetes Atlas. 2006.

   Not in our library

2. 2.

   Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.

   Not in our library10.2337/dc06-9912

3. 3.

   Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, et al. Postprandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese Type 2 diabetic patients. Biochem Biophys Res Commun. 2005;336:339-345.

   Not in our library10.1016/j.bbrc.2005.08.158

4. 4.

   Levitan EB, Song Y, Ford ES, Liu S. Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164:2147-2155.

   Not in our library10.1001/archinte.164.19.2147

5. 5.

   Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10-16.

   Not in our library10.1016/s0195-668x(03)00468-8

6. 6.

   Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in Type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280-285.

   Not in our library10.1016/j.diabres.2006.11.011

7. 7.

   Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229-235.

   Not in our library10.1016/s0021-9150(99)00059-3

8. 8.

   IDF Clinical Guidelines Task Force. Guideline for Management of Postmeal Glucose. 2007.

   Not in our library

9. 9.

   WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. 2006;1-46.

   Not in our library

10. 10.

    Gerich JE. Pathogenesis and treatment of Type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res. 1996;28:404-412.

    Not in our library10.1055/s-2007-979828

11. 11.

    Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 2001;44:929-945.

    Not in our library10.1007/s001250100580

12. 12.

    Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.

    Not in our library10.1172/jci7231

13. 13.

    Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263-269.

    Not in our library10.2337/dc06-1612

14. 14.

    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881-885.

    Not in our library10.2337/diacare.26.3.881

15. 15.

    Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of US adults with Type 2 diabetes. Diabetes Care. 2001;24:1734-1738.

    Not in our library10.2337/diacare.24.10.1734

16. 16.

    Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in Type 1 diabetic patients. Diabetes Res Clin Pract. 2007;75:30-34.

    Not in our library10.1016/j.diabres.2006.05.009

17. 17.

    UK Prospective Diabetes Study, UKPDS, Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

    Not in our library

18. 18.

    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405-412.

    Not in our library10.1136/bmj.321.7258.405

19. 19.

    Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-819.

    Not in our library10.1210/jc.2005-1005

20. 20.

    Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil. 2006;13:555-561.

    Not in our library10.1097/01.hjr.0000183916.28354.69

21. 21.

    DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch Intern Med. 2001;161:397-405.

    Not in our library10.1001/archinte.161.3.397

22. 22.

    Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.

    Not in our library10.1007/s001250050617

23. 23.

    Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.

    Not in our library10.1016/s0735-1097(99)00168-0

24. 24.

    Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. J Am Med Assoc. 2006;295:1681-1687.

    Not in our library10.1001/jama.295.14.1681

25. 25.

    Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004;53:701-710.

    Not in our library10.2337/diabetes.53.3.701

26. 26.

    Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in Type 2 diabetic patients. Circulation. 2005;112:179-184.

    Not in our library10.1161/circulationaha.104.495127

27. 27.

    Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30:561-567.

    Not in our library10.2337/dc06-0922

28. 28.

    Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma glucose excursions and cognitive functioning in aged Type 2 diabetics. Neurology. 2006;67:235-240.

    Not in our library10.1212/01.wnl.0000224760.22802.e8

29. 29.

    Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation. 2004;110:214-219.

    Not in our library10.1161/01.cir.0000134501.57864.66

30. 30.

    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc. 2003;290:486-494.

    Not in our library10.1001/jama.290.4.486

31. 31.

    Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073-1078.

    Not in our library10.1161/01.str.0000125864.01546.f2

32. 32.

    Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS. α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care. 2001;24:726-732.

    Not in our library10.2337/diacare.24.4.726

33. 33.

    Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16:125-132.

    Not in our library10.1002/(sici)1520-7560(200003/04)16:2<125::aid-dmrr90>3.0.co;2-4

34. 34.

    Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25:1439-1443.

    Not in our library10.2337/diacare.25.8.1439

35. 35.

    Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in Type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91:837-842.

    Not in our library10.1210/jc.2005-1566

36. 36.

    Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. 4T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in Type 2 diabetes. N Engl J Med. 2007;357:1716-1730.

    Not in our library10.1056/nejmoa075392

37. 37.

    American Diabetes Association. Clinical practice recommendations 2007: diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30:S42-S47.

    Not in our library10.2337/dc07-s042

38. 38.

    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27:S21.

    Not in our library10.1016/j.jcjd.2013.01.009

39. 39.

    IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2005.

    Not in our library

40. 40.

    Wolever TM, Yang M, Zeng XY, Atkinson F, Brand-Miller JC. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr. 2006;83:1306-1312.

    Not in our library10.1093/ajcn/83.6.1306

Cited by papers we hold 4

• Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study · 2013
  No notice
• Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin · 2013
  No notice
• Impact of postprandial glycaemia on health and prevention of disease · 2012
  No notice
• Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia) · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.